VertexVertexVertex

Vertex

No trades
See on Supercharts

Key facts today

Truist Securities has maintained a 'Buy' rating for Vertex Pharmaceuticals while reducing the price target from $550.00 to $460.00 per share.
Scotiabank maintained Vertex Pharmaceuticals at a Sector Perform rating and raised the price target to $430.00 per share from $426.00.
Analyze the impactAnalyze the impact

See all ideas 

Displays a symbol's price movements over previous years to identify recurring trends.